Is HELP a Buy or a Sell? The Bull and Bear Case (2026)
Last updated October 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for Cybin (HELP) rests on Phase 3 depression readout: The PARADIGM program (APPROACH plus EMBRACE) testing HLP003 in major depressive disorder is the central catalyst. The bear case rests on as a clinical-stage company, Helus has no revenue and posts ongoing net losses (about $171 million over the trailing twelve months as of October 2026), so it depends on trial success and repeated financing to survive. Analysts covering it publish targets from $15.00 to $70.62 against a $10.55 price, so even the professionals disagree by 138% of their own average. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
Helus Pharma Inc., which began trading on the Nasdaq under the ticker HELP in early 2026 (previously CYBN on NYSE American) and completed its legal name change from Cybin Inc. on October 1, 2026 after shareholders approved it on September 22, is a Toronto-based clinical-stage pharmaceutical company. The ticker did not change, and the shares also trade on Cboe Canada. Its lead program is HLP003 (also referenced as CYB003), a deuterated psilocybin analog with FDA Breakthrough Therapy Designation that is being studied as an adjunctive treatment for major depressive disorder in a registrational Phase 3 program called PARADIGM, which includes the APPROACH and EMBRACE studies. A second candidate, HLP004, a deuterated DMT compound, is in Phase 2 for generalized anxiety disorder. These are neuroactive serotonergic molecules designed to be administered in a supervised clinical setting. As a pre-revenue biotech, Helus has no product sales and reports widening net losses as it funds late-stage trials: the net loss for the fiscal year ended March 31, 2026 was about $210 million, up from ~$113 million the year before, and the trailing twelve-month loss is about $171 million. The company held roughly $166 million in cash and no debt at June 30, 2026, giving it a runway measured in quarters rather than years, and it has repeatedly raised equity to extend that runway. The stock closed near $10.73 on October 16, 2026, up about 30% year to date and 76% over the past year, though it is down ~13% in the past month after a run toward its 52-week high of ~$15. The investment picture is binary and event-driven: management expects topline APPROACH data in Q4 2026 and has said it plans to file a New Drug Application in 2028 if the broader Phase 3 program supports it. Positive data and a clear regulatory path could re-rate the stock sharply, while a trial miss, a financing gap, or heavy dilution could impair it. This is a high-risk, high-variance profile typical of psychedelic-medicine developers.
The bull case: what would have to be true for $70.62
The most optimistic published target on HELP is $70.62, +569.4% from the $10.55 price as of October 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
1. Phase 3 depression readout
The PARADIGM program (APPROACH plus EMBRACE) testing HLP003 in major depressive disorder is the central catalyst. As of September 2026 Helus said it expects topline APPROACH results in the fourth quarter of 2026; the study tests two 16 mg doses given three weeks apart, with a primary endpoint at six weeks and a 12-week durability endpoint. In Phase 2, HLP003 showed about a 13-point MADRS effect after one dose. A clean efficacy and safety result would be the most material value driver, since MDD is a large addressable market and few psychedelic therapies have reached Phase 3 data. The company plans an NDA filing in 2028 if the program supports it, and will host an investor presentation on October 21, 2026.
2. Anxiety program optionality
HLP004, a deuterated DMT compound, is in Phase 2 for generalized anxiety disorder. Positive signals here would broaden the pipeline beyond a single depression bet and give the platform a second indication. Helus has also pointed to a next candidate, HLP005, which it expects to advance in 2027.
3. Cash position and financing
Helus held roughly $166 million in cash and no debt at June 30, 2026, down from about $195 million at the end of 2025, with operating cash burn of ~$141 million over the trailing twelve months. That funds its late-stage trials but implies continued reliance on capital markets. The pace of spending versus milestone timing shapes how much additional dilution shareholders may face before any potential approval.
4. Psychedelic-medicine regulatory path
The environment for FDA review of psychedelic and serotonergic therapies is still developing. HLP003's Breakthrough Therapy Designation gives it more frequent agency interaction. Clearer agency guidance and precedent from peers could de-risk the category, while setbacks at competing programs could weigh on sentiment across the space.
The bear case: what would have to be true for $15.00
The most pessimistic published target is $15.00, +42.2% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks Cybin is worth if the risks below bite instead of the drivers above.
As a clinical-stage company, Helus has no revenue and posts ongoing net losses (about $171 million over the trailing twelve months as of October 2026), so it depends on trial success and repeated financing to survive. A Phase 3 miss, ambiguous data, or safety signal for HLP003 would be highly damaging given the concentration in a single lead program, and the Q4 2026 readout is close. Equity raises have diluted existing holders and are likely to continue until the company reaches profitability, which is not forecast in the near term; analysts expect losses through at least fiscal 2028. Regulatory uncertainty around psychedelic therapies, the operational complexity of supervised administration, and competition from other developers add further risk. The stock is volatile (its 52-week range runs from ~$3.76 to ~$15.15) and can move sharply on single data points.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding HELP already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on HELP
10 analysts cover HELP, with an average target of $40.44 (+283.3% against $10.55) and a split of 11 buy, 0 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the HELP forecast and price target page.
How is HELP valued? (as of October 2026)
Snapshot for HELP as of October 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Share price: ~$10.73 (Oct 16, 2026)
- Market cap: ~$784M
- Revenue (TTM): $0 (pre-revenue)
- Net loss (TTM): ~$171M
- Cash: ~$166M, no debt (June 30, 2026)
- Operating cash burn (TTM): ~$141M
- Latest quarter EPS: -$1.26 vs -$1.38 estimate
Standard earnings multiples do not apply because Helus has no revenue and runs at a loss while funding Phase 3 trials. At roughly $784 million, the market value is now well above the ~$166 million cash balance, so investors are assigning a substantial premium to the pipeline ahead of the Q4 2026 Phase 3 data, a bigger bet than earlier in the year. Valuation will hinge on trial outcomes and any resulting financing rather than on current financials.
How do you decide if HELP is a buy?
Rather than asking whether HELP is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold HELP indirectly through an index or sector ETF before adding more.
What would change your mind on HELP
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: Phase 3 depression readout stalls in the reported numbers rather than in the narrative around them.
- Bear case breaks if: as a clinical-stage company, Helus has no revenue and posts ongoing net losses (about $171 million over the trailing twelve months as of October 2026), so it depends on trial success and repeated financing to survive fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the HELP stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about HELP against your real portfolio and see your actual exposure before deciding.
Investing in Cybin with AI
Connect the broker you already use and ask Walnut's AI how HELP fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
Is HELP a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on Phase 3 depression readout, with revenue (ttm) at $0 (pre-revenue). The bear case rests on as a clinical-stage company, Helus has no revenue and posts ongoing net losses (about $171 million over the trailing twelve months as of October 2026), so it depends on trial success and repeated financing to survive. Analysts covering it are spread from $15.00 to $70.62, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.
Should I sell HELP?
+
Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. As a clinical-stage company, Helus has no revenue and posts ongoing net losses (about $171 million over the trailing twelve months as of October 2026), so it depends on trial success and repeated financing to survive. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $15.00, +42.2% from the $10.55 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.
What is the bull case for HELP?
+
Phase 3 depression readout. The PARADIGM program (APPROACH plus EMBRACE) testing HLP003 in major depressive disorder is the central catalyst. The most optimistic analyst target on HELP is $70.62, +569.4% from the $10.55 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for HELP?
+
As a clinical-stage company, Helus has no revenue and posts ongoing net losses (about $171 million over the trailing twelve months as of October 2026), so it depends on trial success and repeated financing to survive. A Phase 3 miss, ambiguous data, or safety signal for HLP003 would be highly damaging given the concentration in a single lead program, and the Q4 2026 readout is close. Equity raises have diluted existing holders and are likely to continue until the company reaches profitability, which is not forecast in the near term; analysts expect losses through at least fiscal 2028. Regulatory uncertainty around psychedelic therapies, the operational complexity of supervised administration, and competition from other developers add further risk. The stock is volatile (its 52-week range runs from ~$3.76 to ~$15.15) and can move sharply on single data points. The most pessimistic published target is $15.00, +42.2% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.
What does Cybin do?
+
Cybin Inc., which began trading on the Nasdaq under the ticker HELP in early 2026 (previously CYBN on NYSE American) and adopted the operating name Helus Pharma, is a Toronto-based
What would have to change for HELP to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Phase 3 depression readout) stalling in the reported numbers rather than in the narrative, the risk above (as a clinical-stage company, Helus has no revenue and posts ongoing net losses (about $171 million over the trailing twelve months as of October 2026), so it depends on trial success and repeated financing to survive) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What company is the ticker HELP?
+
HELP is Helus Pharma Inc., a clinical-stage biotech formerly named Cybin Inc. It moved its U.S. listing to the Nasdaq under HELP in early 2026 after previously trading as CYBN on NYSE American, and its legal name change to Helus Pharma took effect on October 1, 2026. The ticker stayed HELP.
What does Helus Pharma do?
+
It develops psychedelic-derived neuroactive compounds, including a deuterated psilocybin analog and a deuterated DMT analog, designed as supervised therapies for major depressive disorder and generalized anxiety disorder.
Does HELP have any revenue?
+
No. Helus is pre-revenue and reported zero revenue in each of the last four quarters, so it operates at a loss (about $171 million over the trailing twelve months as of October 2026) while funding clinical trials, which is typical for a clinical-stage biotech.
Walnut is informational, not investment advice, and gives no verdict on HELP. Analyst targets referenced here come from a October 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.